Related references
Note: Only part of the references are listed.Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
Boghuma K. Titanji et al.
CLINICAL INFECTIOUS DISEASES (2021)
Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
Dong Huang et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
Of chloroquine and COVID-19
Franck Touret et al.
ANTIVIRAL RESEARCH (2020)
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Xueting Yao et al.
CLINICAL INFECTIOUS DISEASES (2020)
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
Jianjun Gao et al.
BIOSCIENCE TRENDS (2020)
Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies
Myura Nagendran et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
Wei Tang et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta et al.
LANCET (2020)
Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach
Praveen Tilangi et al.
LANCET INFECTIOUS DISEASES (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pandemic publishing poses a new COVID-19 challenge
Adam Palayew et al.
NATURE HUMAN BEHAVIOUR (2020)
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical Trial
Mayla Gabriela Silva Borba et al.
JAMA NETWORK OPEN (2020)
Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning
Xiangxiang Zeng et al.
JOURNAL OF PROTEOME RESEARCH (2020)
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection
J. M. Molina et al.
MEDECINE ET MALADIES INFECTIEUSES (2020)
Hydroxychloroquine for the Prevention of Covid-19-Searching for Evidence
Myron S. Cohen
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
A. B. Cavalcanti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
Franck Touret et al.
SCIENTIFIC REPORTS (2020)
Anakinra for severe forms of COVID-19: a cohort study
Thomas Huet et al.
LANCET RHEUMATOLOGY (2020)
The COVID-19 Drug and Gene Set Library
Maxim Kuleshov et al.
PATTERNS (2020)
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Giovanni Guaraldi et al.
LANCET RHEUMATOLOGY (2020)
Target identification among known drugs by deep learning from heterogeneous networks
Xiangxiang Zeng et al.
CHEMICAL SCIENCE (2020)
DeepFam: deep learning based alignment-free method for protein family modeling and prediction
Seokjun Seo et al.
BIOINFORMATICS (2018)
Deep Learning Applications for Predicting Pharmacological Properties of Drugs and Drug Repurposing Using Transcriptomic Data
Alexander Aliper et al.
MOLECULAR PHARMACEUTICS (2016)
Computational and Practical Aspects of Drug Repositioning
Tudor I. Oprea et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2015)
Lancet retracts 12-year-old article linking autism to MMR vaccines
Laura Eggertson
CANADIAN MEDICAL ASSOCIATION JOURNAL (2010)